Improving regulatory capacity to manage risks associated with trade agreements

Globalization and Health

Peter Drahos³  Richard D Smith¹  Helen L Walls² 

[1] Leverhulme Centre for Integrative Research on Agriculture and Health, London, UK;The Australian National University, Canberra, Australia;Queen Mary University of London, London, UK

关键词: Health inequities;    Regulatory capacity;    Trade agreements;    Trade policy;   

Others  :  1175235
DOI  :  10.1186/s12992-015-0099-7

 received in 2014-12-01, accepted in 2015-03-05,  发布年份 2015

【 摘 要 】

Modern trade negotiations have delivered a plethora of bilateral and regional preferential trade agreements (PTAs), which involve considerable risk to public health, thus placing demands on governments to strengthen administrative regulatory capacities in regard to the negotiation, implementation and on-going management of PTAs. In terms of risk management, the administrative regulatory capacity requisite for appropriate negotiation of PTAs is different to that for the implementation or on-going management of PTAs, but at all stages the capacity needed is expensive, skill-intensive and requires considerable infrastructure, which smaller and poorer states especially struggle to find. It is also a task generally underestimated. If states do not find ways to increase their capacities then PTAs are likely to become much greater drivers of health inequities. Developing countries especially struggle to find this capacity. In this article we set out the importance of administrative regulatory capacity and coordination to manage the risks to public health associated with PTAs, and suggest ways countries can improve their capacity.

【 授权许可】

   
2015 Walls et al.; licensee BioMed Central.

【 参考文献 】

• [1]Douglas A. Free Trade Under Fire. 2nd ed. Princeton University Press, Princeton; 2005.
• [2]Baker P, Kay A, Walls H. Trade and investment liberalization and Asia’s noncommunicable disease epidemic: a synthesis of data and existing literature. Glob Health. 2014; 10(1):66.
• [3]Blouin C, Chopra M, van der Hoeven R. Trade and social determinants of health. Lancet. 2009; 373:502-7.
• [4]Hawkes C. Uneven dietary development: linking the policies and processes of globalization with the nutrition transition, obesity and diet-related chronic diseases. Glob Health. 2006; 2:4. BioMed Central Full Text
• [5]Stuckler D. M N. Big Food, Food Systems, and Global Health. PLoS Med. 2012; 9(6):e1001242. doi: 10. 1371/journal.pmed.1001242
• [6]Baldwin R. 21st Century Regionalism: Filling the gap Between 21st Century Trade and 20th Century Trade Rules. World Trade Organization, Geneva; 2011.
• [7]Kelsey J. New-generation free trade agreements threaten progressive tobacco and alcohol policies. Addiction. 2012; 107:1719-21.
• [8]Staiger R. Non-Tariff Measures and the WTO. 2012.
• [9]Bennet N. Health concerns raised over EU-US trade deal. Lancet. 2014; 384(9946):843-4.
• [10]Gleeson D, Friel S. Emerging threats to public health from regional trade agreements. Lancet. 2013; 381:1507-09.
• [11]Monasterio E, Gleeson D. Pharmaceutical industry behaviour and the Trans Pacific Partnership Agreement. N Z Med J. 2014; 127:6-12.
• [12]Monasterio E, Gleeson D. The Trans Pacific Partnership Agreement: Exacerbation of inequality for patients with serious mental illness. Aust N Z J Psychiatry. 2014; 48(12):1077-1080.
• [13]Gleeson D, Lopert R, Reid P. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand. Health Policy. 2013; 112:227-33.
• [14]Bhardwaj K, Oh C. The Trans-Pacific Partnership Agreement: Implications for Access to Medicines and Public Health. UNITAID; WHO, Geneva; 2014.
• [15]Chan M. Health has an obligatory place on any post-2015 agenda. Address to the Sixty-seventh World Health Assembly 2014 (19 May). Available from: www.who.int/dg/speeches/2014/wha-19052014/en.
• [16]Davies P. Trade secrets: will an EU-US treaty enable US big business to gain a foothold? Br Med J. 2013; 346:t3574.
• [17]Baker B. Threat of pharmaceutical-related IP investment rights in the Trans-Pacific Partnership Agreement: an Eli Lilly v. Canada case study. Investment Treaty News. 2013 http://www.iisd.org/itn/2013/09/20/threat-of-pharmaceutical-related-ip-investment-rights-in-the-trans-pacific-partnership-agreement-an-eli-lilly-v-canada-case-study/.
• [18]Schram A, Labonte R, Khatter K. The Trans-Pacific Partnership agreement and public health: why we should be concerned. Open Med. 2014; 8(3):e100-7.
• [19]Mitchell A, Studdert D. Plain packaging of tobacco products in Australia: A novel regulation faces legal challenge. JAMA. 2012; 307(3):261-2.
• [20]Linh N, Huong N, Thuy H. Evolving trade policy and the Trans-Pacific Partnership Agreement: Does it threaten Vietnam’s access to medicine and its progress towards scaling up HIV prevention, treatment and care? Glob Public Health. 2015; 10(1):s149-60.
• [21]Drahos P, Braithwaite J. Information Feudalism: Who Owns the Knowledge Economy?. Earthscan, London; 2002.
• [22]Capling A, Ravenhill J. Multilateralising retgionalism: what role for the Trans-Pacific Partnership Agreement? Pac Rev. 2011; 24(5):553-75.
• [23]Freund C. Reciprocity in Free Trade Agreements. World Bank, Geneva; 2003.
• [24]Jawara F, Kwa A. Behind the Scenes at the WTO: The Real World of International Trade Negotiations. Zed Books, New York; 2004.
• [25]Buthe T. The Globalization of Health and Safety Standards: Delegation of Regulatory Authority in the SPS Agreement of the 1994 Agreement Establishing the World Trade Organization. Law Contemp Probl. 2008; 71:219.
• [26]Athukorala P, Jayasuriya S. Food safety issues, trade and WTO rules: A developing country perspective. World Econ. 2003; 26(9):1395-416.
• [27]Henson S, Loader R. Barriers to Agricultural Exports from Developing Countries: The Role of Sanitary and Phytosanitary Requirements. World Dev. 2001; 29:85-102.
• [28]Shaffer G. Defending Interests: Public Private Partnerships in WTO Litigation. Brookings Institution Press, Washington DC; 2003.
• [29]Kesselheim A, Mello M, Studdert D. Startegies and practices in off-label marketing of pharmaceuticals: A retrospective analysis of whistleblower complaints. PLOS Medicine. 2011; 8(4):e1000431.
• [30]The Cycle of Action and Reaction: Developments and Trends in Intellectual Property and Health. Earthscan, London; 2006.
• [31]Federal Trade Commission: Fiscal Year 2014, Congressional Budget Justification. 2014.
• [32]The Library of Congress. House Report 113-172 - Financial Services and General Government Appropriations BIll, 2014. Available from: http://thomas.loc.gov/cgi-bin/cpquery/?&sid=cp113mSUfk&r_n=hr172.113&dbname=cp113&&sel=TOC_156437&.
• [33]Department of Justice. Antitrust Division (ATR). Available from: http://www.justice.gov/sites/default/files/jmd/legacy/2013/10/16/fy13-atr-bud-summary.pdf.
• [34]Smith R. The role of economic power in influencing the development of global health governance. Global Health Governance. 2010;3(2).
• [35]Kesselheim A. Intellectual Property policy in the Pharmaceutical Sciences: The Effect of Inappropriate Patents and Market Exclusivity Extensions on the Health Care System. AAPS J. 2007; 9(3):E306-11.
• [36]Browne S. Aid and Influence: do Donors Help or Hinder?. Earthscan, London; 2006.
• [37]Stiglitz J, Charlton A. The Right to Trade: Rethinking the aid for Trade Agenda: Commonwealth Secretariat. 2013.
• [38]Elkins Z, Simmons B. On Waves, Clusters, and Diffusion: A Conceptual Framework. Ann Am Acad Pol Soc Sci. 2005; 598(598):33-51.
• [39]Drahos P. Global Governance of Knowledge: Patent Offices and Their Clients. Cambridge University Press, Cambridge; 2010.
• [40]Thow AM, Annan R, Mensah L, Chowdhury S. Development, implementation and outcome of standards to restrict fatty meat in the food supply and prevent NCDs: learning from an innovative trade/food policy in Ghana. BMC Public Health. 2014; 14(1):249. BioMed Central Full Text
• [41]Estevadoerdal A, Frantz B, Nguyen T. Regional public goods: From Theory to Practice: Inter-American Development Bank. 2004.
• [42]Hoekman B, Mattoo A. Services trade liberalization and regulatory reform: re-invigorating international cooperation. The World Bank. Policy Research Working Paper 5517. 2011.
• [43]Braithwaite J. Responsive regulation and developing economies. World Dev. 2006; 34(5):884-98.